1
Location of HENGRUI The Headquarters: No.7 Kunlunshan Road, Economic & Technological Development Zone Lianyungang, Jiangsu, China 2
Domestic Achievements No. 1 in Market Cap No. 1 in Innovation No. 1 in Antineoplastics No. 1 in Surgical Drugs No. 1 in Finished Dosage Product exporting to Regulated Market No. 1 in Contrast Media 3
Location of HENGRUI 705km to Beijing 468km to Shanghai 1560km to Guangzhou Lianyungang 4
History of HENGRUI 1) 1970 : Lianyungang Pharmaceutical Factory was established 2) 1997 : Jiangsu Hengrui Medicine Co., Ltd. was incorporated 3) 1999: Drug product plant in Lianyungang was started to production 4) 2000 : IPO (600276) 5) 2000 : Shanghai Hengrui Pharmaceutical Co., Ltd. was established 6) 2005: HENGRUI (USA) Ltd. was incorporated 7) 2007: API manufacturing plant in Lianyungang was completed 8) 2011: Chengdu Suncadia Pharmaceuticals Co., Ltd. was established 9) 2014: Hengrui Medical Japan Corp. was established 10) 2014: Cadiasun Pharman GmbH in Germany was established 11) 2015: Suzhou Suncadia Biopharmaceutical Co., Ltd. was established 5
Subsidiary Companies HENGRUI (USA) LTD. (R&D, RA ) Cadiasun Pharman GmbH. (DE) (RA /MAA Holder ) Hengrui Medical Japan Corp. (Sales) Jiangsu Hengrui Medicine Sales (Sales ) Jiangsu Singch Pharmaceutical Co., Ltd. (Sales) Shanghai Hengrui Pharmaceutical Co., Ltd. (R&D, FDF) Chengdu Suncadia Pharmaceuticals Co., Ltd. (R&D, FDF) Chengdu Xinyue Medicine Co., Ltd. (API) Suzhou Suncadia Biopharmaceutical Co., Ltd. (R&D, FDF) Hengrui Callisyn BioMedical-Suzhou (R&D, Medical Device) 6
Global Presence Headquarters LIANYUNGANG, CHINA USA HENGRUI (USA) LTD. GERMANY Cadiasun Pharman GmbH. CHENGDU, CHINA Chengdu Suncadia Chengdu Xinyue JAPAN Hengrui Medical Japan Corp. SHANGHAI Shanghai Hengrui SUZHOU, CHINA Suzhou Suncadia Biopharmaceutical Callisyn BioMedical 7
Main Businesses Line Market Cap:USD15 Billion Main Business: Pharmaceuticals manufacturing, R&D and distribution Main Product Line: Anti-neoplastic drug, Antibiotics, Endocrine, Cardiovascular, Cerebrovascular and Surgical drugs, Contrast Media 8
Employees Constitution Employees Constitution Number Ratio (%) Production 2,258 19% R&D 1.693 15% Administration 749 6% Sales 7000 60% No. of Total Employees 11700 Employee Constitution Educational Status 1% 9% 60% 19% 15% 51% 39% 6% Production R&D PHD Master Administration Sales Bachelor others 9
Major Products for Domestic Market Multiple therapeutic areas Market leader in oncology, surgical drugs, and contrast media 10+ products with revenue of over 16M USD each Major Products Oncology Drugs, 61% Others, 7% Surgical Drugs, 18% Antiinfection Drugs, 14% 10
USD, Million Robust Growth in Sales and Profit 20% + YOY growth in the past few years Profit reached 340 million USD in 2015, despite major price cut by the local government 1,600 1,400 1,200 1,000 800 600 400 Profit 200 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 11
Broad Domestic Sales Network Covering all of 32 provincial regions Strong presence in all major cities 7000 sales representatives Covering all hospitals in top 3 tiers across the country 12
R&D Information Class 1.1 innovative medicine Apatinib launched Ranked as the most innovative home-grown pharmaceutical company Dozens of NMEs under development Focusing on oncology/hematology, metabolic diseases, CV Research Team Facilities Investment IP Pipeline 13
R&D Centers USA Lianyungang Chengdu Shanghai USA: Focus on world-leading and potential research Shanghai: Upstream work of innovative drug research such as NCEs Lianyungang: Technical study of innovative drugs, and formulation of quality standards Chengdu: R&D of high-activity, hormone and contrast agents Clinical Research Dept.: Drug clinical test 14
USD, Million Strong Commitment to R&D Innovation Annual R&D spending: 8-10% of the sales With a CAGR of around 25% in recent years About 138 million USD investment to R&D in 2015 Commitment to R&D 140 120 100 80 60 40 20 0 2011 2012 2013 2014 2015 15
Intellectual Property Over 250 patent applications so far for its innovative product/technology China patents: 271 filed and 104 issued PCT patents: 111 filed and 104 issued No. of Patents Issued in Recent Years 35 30 25 20 15 10 China patent PCT 5 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 16
Manufacturing Plants Plant 1 Lianyungang API Plant Plant 8 Chengdu API Plant Plant 2 Lianyungang No. 1 FDF Plant Plant 3 Lianyungang No. 2 FDF Plant Plant 7 Chengdu FDF Plant Plant 4 Shanghai FDF Plant Plant 6 Suzhou Medical Device Plant Plant 5 Suzhou FDF Plant Plant 1: 184, 000 m2, US FDA, EDQM, TGA and PMDA approval site Plant 2: 67, 000 m2, US FDA, EDQM, and PMDA approval site Plant 3: 217, 000 m2, biological gene drug production base, US FDA approval site Plant 4: 60, 000 m2, US FDA, EDQM approval site Plant 5: around 110, 000m2, newly built in 2015 Plant 6: medical devices for minimal invasive/ interventional treatment, built in 2006 Plant 7: 100, 000 m2, newly built in 2012 Plant 8: 67, 000 m2, newly built in 2012 17
API FDA EDQM PMDA TGA Cyclophosphamide Etoposide Ifosfamide Irinotecan HCl Sevoflurane Cyclophosphamide Etoposide Ifosfamide Letrzozole Oxaliplatin Irinotecan HCl Letrozole Oxaliplatin 18
Cyclophosphamide for Inj. Letrozole Tab. Irinotecan HCl Inj. Gabapentin Cap. Oxaliplatin Inj. Sevoflurane Inhalation Anaesthetic FDA Letrozole Tab. Irinotecan HCl Inj. PMDA Cyclophosphamide for Inj. Letrozole Tab. Oxaliplatin for Inj. Sevoflurane Inhalation Anaesthetic Caspofungin Acetate for Inj. EDQM 19
ANVISA BRAZIL KFDA KOREA MCC SOUTH ARFICA COFEPRIS MEXICO Other Countries As a leading pharmaceutical company, HENGRUI business has almost covered all countries 20
Partners Worldwide 21
22